Novo Nordisk Provides Update On The Zeus Phase 3 Trial In People With ASCVD, CKD And Inflammation
Adverse Event Rates Similar; Higher Serious Infections With Ziltivekimab Outcome Of Zeus Will Not Impact Novo Nordisk eur S Previously Communicated Adjusted Operating Profit Outlook For 2026 Outcome Will Result In A Non-Cash Impairment Charge In Q3 2026 While Ziltivekimab Demonstrated Target Engagement And Inhibition O